Astuprotimut-R

Summary

Astuprotimut-R (CHEMBL2108705) is a phase-3 clinical-stage unknown; indicated across 6 conditions including non-small cell lung carcinoma and cutaneous melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 6 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108705
Name	Astuprotimut-R
Type	Unknown
Max phase	3

Also known as: Astuprotimut r, Astuprotimut-r, GSK-1572932A, GSK-249553, GSK1572932A, Hp3tut3x8x, Mage a3 protein, Mage a3 recombinant protein, MAGE-A3, Mage-a3 asci, Mage-a3 recombinant protein, SB-249553

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
cutaneous melanoma	2	MONDO:0005012	EFO:0000389
melanoma	2	MONDO:0005105	EFO:0000756
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
head and neck squamous cell carcinoma	1	MONDO:0010150	EFO:0000181

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE1	3
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00090493	PHASE2/PHASE3	COMPLETED	Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma
NCT01245673	PHASE2	COMPLETED	Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
NCT00257738	PHASE1	COMPLETED	0804 GCC: MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
NCT00455572	PHASE1	TERMINATED	Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer
NCT01498172	PHASE1	COMPLETED	BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).